Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery-Reference-Cited by-同舟云学术

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

Published:2015-03-12 Issue:8 Volume:6 Page:5501-5516
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Fu Lei-lei¹,Tian Mao¹,Li Xiang¹,Li Jing-jing¹,Huang Jian²,Ouyang Liang¹,Zhang Yonghui¹³,Liu Bo¹

Affiliation:

1. State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, Department of Urology, West China Hospital, Sichuan University, Chengdu, China

2. School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China

3. Collaborative Innovation Center for Biotherapy, Department of Pharmacology & Pharmaceutical Sciences, School of Medicine, Tsinghua University, Beijing, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 201 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the Role of Bromodomain and Extra-Terminal Proteins in Human Uterine Leiomyosarcoma;Cells;2024-08-28

2. Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling;International Journal of Cancer;2024-07-12

3. BET Inhibitor JQ1 Selectively Reduce Tregs by Upregulating STAT3 and Suppressing PD‐1 Expression in Patients with Multiple Myeloma;Advanced Biology;2024-05-26

4. Discovery of indole-2-one derivatives as BRD4 (BD1) selective inhibitors;Bioorganic & Medicinal Chemistry;2024-05

5. Enhanced cellular therapy: revolutionizing adoptive cellular therapy;Experimental Hematology & Oncology;2024-04-25